Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Value of MGMT Promoter Methylation and TP53 Mutation in Glioblastomas Depends on IDH1 Mutation

  • Wang, Kai (Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University) ;
  • Wang, Yin-Yan (Beijing Neurosurgical Institute) ;
  • Ma, Jun (Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University) ;
  • Wang, Jiang-Fei (Beijing Neurosurgical Institute) ;
  • Li, Shao-Wu (Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University) ;
  • Jiang, Tao (Beijing Neurosurgical Institute) ;
  • Dai, Jian-Ping (Department of Neuroradiology, Beijing Tian Tan Hospital, Capital Medical University)
  • Published : 2015.01.22
Download PDF
⟨ Previous Next ⟩

Abstract

Several molecular markers have been proposed as predictors of outcome in patients with glioblastomas. We investigated the prognostic significance of $O^6$-methylguanine-DNA methyltransferase (MGMT) promoter methylation and TP53 mutation status dependent on isocitrate dehydrogenase 1 (IDH1) mutation in glioblastoma patients. A cohort of 78 patients with histologically confirmed glioblastomas treated with radiation therapy and chemotherapy were reviewed retrospectively. We evaluated the prognostic value of MGMT promoter methylation and TP53 mutation status with regard to progression-free survival (PFS) and overall survival (OS). It was revealed that mutations in IDH1, promoter methylation of MGMT, TP53 mutation, age, Karnofsky performance status (KFS), and extension of resection were independent prognostic factors. In patients with an IDH1 mutation, those with an MGMT methylation were associated with longer PFS (p=0.016) and OS (p=0.013). Nevertheless, the presence of TP53 mutation could stratify the PFS and OS of patients with IDH1 wild type (p=0.003 and 0.029 respectively, log-rank). The MGMT promoter methylation and TP53 mutation were associated with a favorable outcome of patients with and without mutant IDH1, respectively. The results indicate that glioblastomas with MGMT methylation or TP53 mutations have improved survival that may be influenced by IDH1 mutation status.

Keywords

References

  1. Bello MJ, Alonso ME, Aminoso C, et al (2004). Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res, 554, 23-32. https://doi.org/10.1016/j.mrfmmm.2004.02.011
  2. Bleeker FE, Atai NA, Lamba S, et al (2010). The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol, 119, 487-94. https://doi.org/10.1007/s00401-010-0645-6
  3. Butowski NA, Chang SM (2006). Glial tumors: the current state of scientific knowledge. Clin Neurosurg, 53, 106-13.
  4. Carrillo JA, Lai A, Nghiemphu PL, et al (2012). Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Am J Neuroradiol, 33, 1349-55. https://doi.org/10.3174/ajnr.A2950
  5. Dunn GP, Andronesi OC, Cahill DP (2013). From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurg Focus, 34, 2.
  6. Groenendijk FH, Taal W, Dubbink HJ, et al (2011). MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol, 101, 405-17. https://doi.org/10.1007/s11060-010-0274-x
  7. Hartmann C, Hentschel B, Wick W, et al (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol, 120, 707-18. https://doi.org/10.1007/s00401-010-0781-z
  8. Hegi ME, Diserens AC, Gorlia T, et al (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 352, 997-1003. https://doi.org/10.1056/NEJMoa043331
  9. Jesien-Lewandowicz E, Jesionek-Kupnicka D, Zawlik I, et al (2009). High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. Cancer Genet Cytogenet, 188, 77-82. https://doi.org/10.1016/j.cancergencyto.2008.09.015
  10. Juratli TA, Kirsch M, Geiger K, et al (2012). The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol, 110, 325-33. https://doi.org/10.1007/s11060-012-0977-2
  11. Koca T, Basaran H, Sezen D, et al (2014). Comparison of linear accelerator and helical tomotherapy plans for glioblastoma multiforme patients. Asian Pac J Cancer Prev, 15, 7811-6. https://doi.org/10.7314/APJCP.2014.15.18.7811
  12. Lee Y, Scheck AC, Cloughesy TF, et al (2008). Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics, 1, 52. https://doi.org/10.1186/1755-8794-1-52
  13. Levidou G, El-Habr E, Saetta AA, et al (2010). P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature. J Neurooncol, 100, 363-71. https://doi.org/10.1007/s11060-010-0204-y
  14. Li S, Jiang T, Li G, Wang Z (2008). Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res, 30, 567-70. https://doi.org/10.1179/174313208X297913
  15. Minniti G, Salvati M, Arcella A, et al (2011). Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol, 102, 311-6. https://doi.org/10.1007/s11060-010-0324-4
  16. Molenaar RJ, Verbaan D, Lamba S, et al (2014). The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol, 16, 1263-73. https://doi.org/10.1093/neuonc/nou005
  17. Munoz DM, Guha A (2011). Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas. Oncotarget, 2, 590-8. https://doi.org/10.18632/oncotarget.319
  18. Munoz DM, Tung T, Agnihotri S, et al (2013). Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner. Glia, 61, 1862-72. https://doi.org/10.1002/glia.22563
  19. Nagy E, Gajjar KB, Patel, II, et al (2014). MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases. Br J Cancer, 110, 2874-80. https://doi.org/10.1038/bjc.2014.263
  20. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res, 15, 6002-7. https://doi.org/10.1158/1078-0432.CCR-09-0715
  21. Noushmehr H, Weisenberger DJ, Diefes K, et al (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell, 17, 510-22. https://doi.org/10.1016/j.ccr.2010.03.017
  22. Ohgaki H, Kleihues P (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol, 170, 1445-53. https://doi.org/10.2353/ajpath.2007.070011
  23. Ohgaki H, Kleihues P (2009). Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci, 100, 2235-41. https://doi.org/10.1111/j.1349-7006.2009.01308.x
  24. Olson RA, Brastianos PK, Palma DA (2011). Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J Neurooncol, 105, 325-35. https://doi.org/10.1007/s11060-011-0594-5
  25. Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12. https://doi.org/10.1126/science.1164382
  26. Pashaki AS, Hamed EA, Mohamadian K, et al (2014). Efficacy of high dose radiotherapy in post-operative treatment of glioblastoma multiform-a single institution report. Asian Pac J Cancer Prev, 15, 2793-6. https://doi.org/10.7314/APJCP.2014.15.6.2793
  27. Phillips HS, Kharbanda S, Chen R, et al (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9, 157-73. https://doi.org/10.1016/j.ccr.2006.02.019
  28. Sanson M, Marie Y, Paris S, et al (2009). Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol, 27, 4150-4. https://doi.org/10.1200/JCO.2009.21.9832
  29. Sarmiento JM, Nuno M, Ortega A, et al (2014). Cystic glioblastoma: an evaluation of IDH1 status and prognosis. Neurosurgery, 74, 71-5: discussion 5-6. https://doi.org/10.1227/NEU.0000000000000200
  30. Sathornsumetee S, Rich JN, Reardon DA (2007). Diagnosis and treatment of high-grade astrocytoma. Neurol Clin, 25, 1111-39. https://doi.org/10.1016/j.ncl.2007.07.004
  31. SongTao Q, Lei Y, Si G, et al (2012). IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci, 103, 269-73. https://doi.org/10.1111/j.1349-7006.2011.02134.x
  32. Soussi T, Wiman KG (2007). Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell, 12, 303-12. https://doi.org/10.1016/j.ccr.2007.10.001
  33. Stancheva G, Goranova T, Laleva M, et al (2014). IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Biomed Res Int, 2014, 654727.
  34. Stander M, Peraud A, Leroch B, Kreth FW (2004). Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer, 101, 1028-35. https://doi.org/10.1002/cncr.20432
  35. Stupp R, Hegi ME, Mason WP, et al (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10, 459-66. https://doi.org/10.1016/S1470-2045(09)70025-7
  36. Su Y, Yin L, Liu R, et al (2014). Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma. Med Oncol, 31, 784. https://doi.org/10.1007/s12032-013-0784-4
  37. Tabatabai G, Stupp R, van den Bent MJ, et al (2010). Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol, 120, 585-92. https://doi.org/10.1007/s00401-010-0750-6
  38. Turcan S, Rohle D, Goenka A, et al (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483, 479-83. https://doi.org/10.1038/nature10866
  39. van den Bent MJ, Gravendeel LA, Gorlia T, et al (2011). A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res, 17, 7148-55. https://doi.org/10.1158/1078-0432.CCR-11-1274
  40. Verhaak RG, Hoadley KA, Purdom E, et al (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17, 98-110. https://doi.org/10.1016/j.ccr.2009.12.020
  41. Weller M, Felsberg J, Hartmann C, et al (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol, 27, 5743-50. https://doi.org/10.1200/JCO.2009.23.0805
  42. Wick W, Meisner C, Hentschel B, et al (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81, 1515-22. https://doi.org/10.1212/WNL.0b013e3182a95680
  43. Yan W, Zhang W, You G, et al (2012). Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One, 7, 30339. https://doi.org/10.1371/journal.pone.0030339

Cited by

  1. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma vol.126, pp.2, 2016, https://doi.org/10.1007/s11060-015-1978-8
  2. p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors vol.41, pp.2, 2018, https://doi.org/10.1007/s13402-017-0361-5